



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Levetiracetam

October 17, 2017

Non-proprietary name

Levetiracetam

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Neuroleptic malignant syndrome:

Neuroleptic malignant syndrome may occur. If pyrexia, muscle rigidity, increased creatinine kinase (creatinine phosphokinase), tachycardia, blood pressure fluctuation, disturbed consciousness, excess sweating, increased white blood cells, etc. are observed, administration of this drug should be discontinued and appropriate measures such as cooling of the body, hydration, respiratory management, etc. should be taken. Decreased renal function with myoglobinuria may also occur.